Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Cash from Operations (2016 - 2025)

Fate Therapeutics (FATE) has disclosed Cash from Operations for 14 consecutive years, with 23314000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Operations rose 16.13% year-over-year to 23314000.0, compared with a TTM value of 106084000.0 through Dec 2025, up 13.66%, and an annual FY2025 reading of 106084000.0, up 13.66% over the prior year.
  • Cash from Operations was 23314000.0 for Q4 2025 at Fate Therapeutics, up from 24374000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 23314000.0 in Q4 2025 and bottomed at 75389000.0 in Q4 2022.
  • Average Cash from Operations over 5 years is 38614950.0, with a median of 32828000.0 recorded in 2024.
  • The sharpest move saw Cash from Operations plummeted 240.17% in 2021, then skyrocketed 55.33% in 2023.
  • Year by year, Cash from Operations stood at 70293000.0 in 2021, then dropped by 7.25% to 75389000.0 in 2022, then surged by 51.4% to 36637000.0 in 2023, then rose by 24.12% to 27799000.0 in 2024, then increased by 16.13% to 23314000.0 in 2025.
  • Business Quant data shows Cash from Operations for FATE at 23314000.0 in Q4 2025, 24374000.0 in Q3 2025, and 24587000.0 in Q2 2025.